

Subject Index to Volume 6 (1989)

- (thr 1)-muramyl dipeptide, 748
β-adrenoceptor antagonist, metoprolol, 152
α-aminoboronic acid derivatives, aminopeptidase inhibitors, 186
β-elimination, protein degradation, 903
α₁-acid glycoprotein binding of acidic and basic drugs, 156
α₁-acid-glycoprotein (orosomucoid), 107
2',3'-didehydro-3'-deoxythymidine plasma levels, rat, monkey, 895
2',3'-didehydro-3'-deoxythymidine, HPLC, 895
3-hydroxymethyl phenytoin, 555
3-hydroxymorphinan, 13
3-methoxymorphinan, 13
5-bromoindole, NMR, 531
5-fluorouracil prodrug, 5'-deoxy-5-fluorouridine, 323
5-fluorouracil prodrugs, 318
5-iodo-2'-deoxyuridine 5'-ester prodrugs, 887
5-methyl-10,11-dihydro-5H-dibenzo (a,d)-cyclohepten-5,10-imine, 474
5'-deoxy-5-fluorouridine, rectal administration, 318
5'-deoxy-5-fluorouridine, absorption from colon, 323
1,6-hexamethylene diamine, 714
99mTechnecium-sulfur colloid, 719
111In-labeled hydroxypropylmethylcellulose, 274
- absorption enhancement, rectal, 91
absorption enhancement, sodium taurodihydrofusidate, 853
absorption enhancer, medium chain glycerides, 91
absorption of 5'-deoxy-5-fluorouridine, from colon, 323
absorption rate constant, apparent zero order, 133
ACE inhibitor, 759
acetaminophen, hepatotoxicity, 1025
acetylation procainamide metabolite, 477
acetylcholine esterase inhibitor, tacrine, 924
acetylcholine-brain levels, mice, 709
acetylcholinesterase, inhibition by H2 antagonist, 709
acid-base equilibria, piperazines, 177
activation energy, water transport, 564
acyclovir, blood brain barrier, 624
acyl migration, glucuronides, 125
adduct formation, teicoplanin, 1032
adinazolam, metabolism in elderly subjects, 379
adinazolam, pharmacokinetics, 379
adjuvant, muramyl dipeptide activity, 748
adsorption, protein stability, 903
aerosol inhalation, 227
age, effect on skin barrier, 949
aggregation, protein stability, 903
aging, pharmacokinetics and pharmacodynamics, 379
agranulocytosis, reactive metabolites, 265
ajmaline, circular dichroism, 521
albumin, 107
albumin, cationized, glycosylated, 466
albumin, lactosylated, 110
alginate, sodium, 413
alkanes, distant matrix, 809
Alzheimer's disease, tacrine, 924
aminoglycosides, interaction with phospholipids, 362
aminopeptidase, buccal epithelium, 161
aminopeptidase, hamster cheek pouch, 966
aminopeptidase, inhibitors, -aminoboronic acids, 186
aminopeptidase, inhibitors, bestatin, 186
aminouracil derivatives, cardiovascular activity, 394
aminouracil diuretic, 394
aminouracil synthesis, 394
amoxicillin, otitis media, pharmacokinetics, 279
amphoteric gel, 44
analgesia, N-phosphinylamino-1,2,5,6-tetrahydropyridines, 737
analgesic activity, NSAID, 867
androgen, substitutional therapy, 641
angiotensin converting enzyme (ACE) inhibitor, moexipril, 971
angiotensin converting enzyme (ACE) inhibitors, 1043
angiotensin converting enzyme inhibitor, CGS 16617, bioavailability, 328
angiotensin converting enzyme, inhibitors, 759
anhydro-daptomycin, 387
anion-exchange copolymer, colestipol, 619
anthelmintic agents in rats, CDRI81-470, 991
antiarrhythmic activity, n-alkyl-1,2-diphenylethanolamines, 254
antiarrhythmic activity, verapamil, 254
antibiotics, in otitis media, 279
anticholinergic, scopolamine, 481
antiemetic, scopolamine, 481
antiepileptic, valpromide, 683
antihistamines, antiperspirant, 883
antimicrobial pharmacokinetics in otitis media, 279
antiperspirancy, H1 blockers, 883
antipyrene, blood brain barrier, 624
area function method, 133
Arrhenius behavior, swelling ratio constants, 564
asialoglycoproteins hepatic uptake, 106
asialoglycoproteins, RME, 194
aspirin, pharmacokinetics, 660
aspartyl peptides, stability, 903
aspartyl transpeptidation, daptomycin, 387
atenolol, cerebral distribution, 250
atenolol, nonlinear pharmacokinetics, 250
atherosclerotic rabbits, lipid disposition, 1011
atrial natriuretic polypeptide, RME, 194
atropine sulfate, antiperspirant, 883
autoradiography, tacrine, 924
azidothymidine, pharmacokinetics, rats, 734
azo-reduction, sulfasalazine, 1067
azone, effect, dose-dependent, on skin permeability, 798
azone, penetration enhancer, 286
- Balaban's J index, 809
barbiturates, metabolism to N-glucosides, 458
basolateral membrane, transport, 954
benoxaprofen, glucuronides, stereochemistry, 125
benoxaprofen, toxicity, 265
benzodiazepine receptors, in hyperthyroidism, 404
benzodiazepines, endogenous origin, 1
benzodiazepines, natural products, 1
bestatin, aminopeptidase inhibitor, 186, 966
beta-blocker, atenolol, CSF levels, 250
beta-blockers, skin permeation, 628
betamethasone 17-valerate, HPLC, 431
betamethasone 21-valerate stability assay, 431
bile salt adsorption, colestipol, 619, 794
biliary excretion, 140
bioavailability by semisimultaneous drug administration, 817
bioavailability evaluation, 817
bioavailability in linear and nonlinear systems, 4
bioavailability trials, 328
bioavailability, 5'-deoxy-5-fluorouridine in rat, 323
bioavailability, cyclosporin, 40
bioavailability, etoposide, 408
bioavailability, furegrelate, 53

- bioavailability, indomethacin, 44
bioavailability, insulin-collagen, 813
bioavailability, naproxen, 919
bioavailability, phenylpropranolamine, 274
bioavailability, scopolamine, 481
bioavailability, theophylline, dogs, 1039
biodegradable microspheres, 296
blood-brain barrier, in vitro model, 624
blood-brain barrier, NSAID, 667
blood-brain barrier, protein permeability, in vitro model, 466
body weight, estradiol, 592
boundary conditions, dissolution, 436
brain microvessel endothelial cells, 624
brain-enhanced chemical delivery system, 592
brittleness, sucrose, 373
brush border membrane, 308
brush-border membrane vesicles, rat intestinal, 302
buccal absorption, leucine-p-nitroanilide, 966
buccal epithelium, drug permeability, 160
buthionine sulfoxime, 1025
- cadaver skin, 825
caffeine, blood brain barrier, 624
caffeine, skin penetration, 628
calcium ions, lipolysis, 449
calorimeters, 20
calorimetry, conduction, 20
calorimetry, heat, 20
carbamazepine dihydrate, x-ray diffraction, 1017
carbamazepine, dissolution, 612
carbamazepine, x-ray diffraction, 1017
carbidopa, coadministration with L-dopa, 501
carbonic anhydrase, sulfonamides binding, 205
carboplatin, methotrexate interaction, 492
cardiac arrhythmia, calcium induced, rat, 254
cardiovascular reactivity, racial differences, 182
carrier-mediated intestinal absorption, ACE inhibitors, 1043
carrier-mediated transport, vincristine, 690
CDRI compound 81-470, HPLC, 991
cefazolin, 486
ceftacor, uptake by intestinal brush border membrane vesicle, 305
ceftibuten, characteristics of, 302
cellulose acetate butyrate-coated microcapsules, 517
cellulose acetate propionate, microspheres, 418
cellulose ethers, 313
centchroman, HPLC, 1048
centchroman, single-dose pharmacokinetics, 1048
cephalosporin, intestinal transport, 302
cephalosporin, membrane transport, 308
cephem, derivative, membrane transport, 308
cephradine, intestinal absorption, 1043
cerebrospinal fluid, atenolol levels, 250
CH COSY, NMR, 531
chemical drug delivery system through BBB, 667
chitosan, microencapsulation, 413
chloramphenicol-induced aplastic anemia, 269
chloroquine blood level, in mice, 787
chloroquine, liposome-encapsulated, 787
chlorpheniramine, antiperspirant, 883
chlorprothixene geometric isomers (cis/trans isomers), 706
cholesterol lowering effect of colestipol, 794
cholesterol, biosynthesis, 232
cholesteryl ester, nonhydrolyzable, 1011
cholinergic activity of H2-antagonist, 709
ciclosporin solubilization, 958
circular dichroism α_1 -acid glycoprotein, 156
circular dichroism, reserpine, 521
cisplatin, lipiodol suspension, 342
cisplatin, localization in tumor, 342
citrate adsorption to colestipol, 796
clearance, intrinsic intestinal absorption clearance, 1056
clofibrate in atherosclerotic rabbits, 1011
clofibrate, dissolution, 612
clonidine, transdermal transport, 443
cluster analysis, neuroleptic receptor binding, 571
coated pits, 106
colchicine, hepatic uptake, 237
colchicine, microtubular, 237
colestipol anion adsorption competition, 794
colestipol hydrochloride, bile salt adsorption, 619, 794
colestipol in atherosclerotic rabbits, 1011
collagen, insulin co-injection, 813
collagenase-like peptidase, in subcutaneous tissue, 813
colloidal polymer dispersions, aqueous, 725
colon tumors in rats, 5'-deoxy-5-fluorouridine, 318
colon, absorption of 5'-deoxy-5-fluorouridine, 323
colon-targeted delivery, naproxen, 919
compartmental models, 260
compartmental models, linear and nonlinear kinetics, 4
compressibility, polyvinylalcohol methyl acrylate copolymer, 844
concentration-effect relationship, barbiturates, 976
conjugation, diglucuronide, 28
connective index, 497
contraceptive drugs, transdermal delivery, 1000
controlled release of drugs, 241
controlled release, dapsone, 945
controlled release, phenylpropranolamine, 274
controlled release, propranolol, 753
controlled release, theophylline, 1039
controlled-release formulation, enalapril, 760
controlled-release formulation, moexipril, 760
copolymers, polyvinyl alcohol-methyl acrylate, 844
corneal membrane permeability, 887
cortisone acetate dissolution, 612
COSY, NMR spectra, 30, 531
covalent protein binding of drugs, 105
creatinine kinase, myotoxicity, 766
cunninghamella elegans, warfarin metabolism, 982
cyclic GMP, endothelium derived relaxing factors, 651
cyclic imides, hypolipidemic activity, 232
cyclodextrin-containing formulation, 641
cyclodextrin-testosterone, 641
cyclosporine, acute toxicity, 601
cyclosporine, formulation, 602
cyclosporine, intestinal absorption, 40
cyclosporine, liposomes, 601
cyclosporine, pharmacokinetics in rats, 254
cyclosporine, pharmacokinetics, dogs, 601
cyclosporine, solubilization, 958
cystic fibrosis, drug development, 525
- d-tubocurarine, protein binding, 111
dapsone micropellets, 945
dapsone toxic reactions, 271
dapsone, dissolution profile, 945
daptomycin, stability, 387
deamination, protein degradation, 903
debrisoquin 4-hydroxylation, 13
decomposition kinetics, by calorimetry, 20
deformation kinetics, sucrose crystals, 1060
denaturation, protein stability, 903
dermal irritation test, contraceptive patches, 1000
desacetyldiltiazem, HPLC in plasma, 428
desmethyldiazepam, natural products, 1
dextran ester prodrugs, naproxen, 919, 995
dextran, fluid phase marker, 71
dextran, glutathione conjugate, 1025
dextranases, g.i. tract, 995
dextromethorphan, conjugation, 13
dextromethorphan, polymorphic metabolism, 13
dextrose, teicoplanin adducts, 1032
diazepam, binding to α_1 -acid glycoprotein, 156
diazepam, gas chromatography/mass spectrometry, 2
diazepam, i.v. formulation, toxicity, 510
diazepam, myotoxicity upon i.m. injection, 167
diazepam, natural products, 1
diazepam, submicronized emulsion, 510

- diazepam, venous sequelae after injection, 510
 differential scanning calorimetry, 798
 diffusion cell, 431
 diffusion model, 931
 diglucuronide, nalmefene, 28
 dihydropyridine prodrugs, NSAID, 667
 dilantin, myotoxicity upon i.m. injection, 167
 diltiazem, HPLC in plasma, 428
 dipeptide transport, 308
 dipeptides, hydrolysis in intestinal tissue, 69
 dipeptides, intestinal permeability, 66
 diphenhydramine, antiperspirant, 883
 diphenylhydramine, lung binding, 877
 dissociation constants, narcotic analgesics, 147
 dissolution kinetics, 438
 dissolution of drugs from transdermal patches, 346
 dissolution of ionizable drugs, 436
 dissolution of water-insoluble drugs, 612
 dissolution profile, water-insoluble drug dosage forms, 612
 dissolution with sodium lauryl sulfate, 612
 dissolution with surfactants, 612
 dissolution, etoposide, 408
 distance matrix, alkanes, 809
 distribution volumes, cefazolin, tobramycin, 486
 disulfide exchange, protein, 903
 dodecyl,N,N-dimethylamino acetate, penetration enhancer, 443
 dopamine agonist, fenoldopam, 702
 dopamine, delivery by ion exchange, 96
 dopamine, HPLC, 97
 dose ranging, pharmacokinetics, zidovudine, 734
 doxorubicin, hepatic first-pass effect, 833
 drug delivery, ion exchange, 96
 drug delivery, liposomes, 633
 drug delivery, transdermal, 355
 drug metabolism, epidermal, 33
 drug release, poly(vinyl alcohol)micromatrices, 578
 drug release, swellable micromatrices, 578
 drug response, racial differences, 182
 drug targeting to the liver, 105
 drug targeting, kinetic model, 367
 drug transport, transdermal, 33
 drug-nutrient interactions, 332
- EDTA, peptidase inhibitor, 91
 eigenvalue of the distance matrix (DI), 809
 elderly subjects, adinazolam, 379
 electron microscopy, buccal epithelium, 161
 electroosmosis, 85
 elimination kinetics of drugs, first order and nonlinear, 260
 emulsion diazepam, 510
 emulsion dosage form, cyclosporine, 40
 emulsion processing, 748
 emulsion stability, 748
 emulsion vehicle, adjuvant muramyl dipeptide, 748
 emulsion, droplet size, 40
 emulsion, ethyloleate, 555
 emulsion, phenytoin prodrugs, 555
 emulsion, triglyceride, 555
 emulsion, triglyceride/lecithin, 449
 enalapril, controlled release, 759
 enalapril, intestinal absorption, 1043
 enalapril, site specific absorption, 759
 enalaprilat, controlled release, 759
 enalaprilat, site specific absorption, 759
 endocytosis, adsorption, 466
 endocytosis, fluid phase, 466
 endocytosis, receptor mediated, 105, 194
 endorphins, des-enkephalin- γ -endorphin, 91
 endosome, 106
 endothelial cell monolayers, bovine brain microvessel, 624
 endothelial cells, bovine brain capillary, 466
 endothelium-derived relaxing factor, 651
 epidermal growth factor, endocytosis
 epidermal growth factor, pharmacokinetic model, 194
 epidermal growth factor, receptor down regulation, 194
 epidermis and dermis separation, 740
 epidermis, human, ultrasound, 697
 epidermis, transport and metabolism, 119
 epithelial cell monolayer, madin darby canine kidney cells, 71, 78
 epithelium, buccal, primary culture, 160
 equal absorption and elimination rate constants, 731
 erosion control, oxprenolol release, 313
 erythrocyte barrier, hepatic elimination, 833
 erythrocytes, sulfonamide binding, 205
 ester prodrugs, NSAID, 867
 esterase inhibitors, 38
 esterase, in epidermis, 119
 estradiol, chemical delivery system, 592
 estradiol, CNS effects in rats, 592
 estrone, blood brain barrier, 624
 ethanol, myotoxicity, 766
 ethyl cellulose, micropellets, dapsone, 945
 ethylene vinyl acetate copolymers, drug delivery, 938
 etoposide, bioavailability, 408
 etoposide, preformulation, 408
 etoposide, solubility, 408
 exocytosis, 106
 extensor digitorum longus, myotoxicity in rat, 167
- f-Met-Leu-Phe, chemotaxis, 78
 fatty acids, biosynthesis, 232
 fatty acids, protein binding, 111
 fatty acids, skin penetration enhancers and irritants, 246
 fatty acids, skin penetration, 628
 fenoldopam, intrarenal formation from its metabolites, 702
 fenoldopam, renal excretion, 702
 fentanyl, solubility and dissociation constants, 147
 fiber membrane, ion exchange drug delivery, 96
 flufenamic acid, binding to α_1 -acid glycoprotein, 156
 fluid-phase endocytosis, 466
 fluid-phase markers, 71
 flunitrazepam, anticonvulsant effect, 585
 flunitrazepam, kinetics-dynamics, 585
 flunitrazepam, receptor binding-effect, rats, 585
 fluorescein isothiocyanate dextran, 160
 fluorescein, model drug in aerosol, 227
 food effects, bioavailability in dogs, 1039
 food intake, estradiol, 592
 formulation design, in vitro/in vivo, contraceptive drugs, 1000
 fosinopril, intestinal absorption, 1043
 fourier transform-infrared/attenuated total reflectance (FT-IR/ATR), 608
 fracture toughness, sucrose, 373
 freeze drying, sucrose, 961
 furegrelate, HPLC, 53
 furegrelate, oral administration, 53
 furegrelate, pharmacokinetics in humans, 53
- gamma scintigraphy, 125I-cholesteryl iopanoate, 1011
 gamma scintigraphy, GI transit, 719
 ganciclovir, blood brain barrier, 624
 gas chromatography/mass spectrometry, nitrosamines, 892
 gastric emptying, dogs, 506
 gastric irritancy, 44
 gastric residence time, 719
 gastric residence time, erodible device, 506
 gastric retention device, 506
 gastric ulcer, indomethacin, 44
 gastrointestinal (GI) tract, pig, 995
 gastrointestinal erosion, NSAID, 867
 gastrointestinal transit by scintigraphy, 274
 gel formulation, nitrosamine content, 892
 gel, amphoteric, indomethacin, 44
 gelatin beadlets, succinylsulfathiols, 517
 gelatin matrices, swelling, 564
 gelatin microspheres, interferon, 422
 gelatin precoating of microspheres, 296
 gender difference, barbiturate pharmacodynamics, 976

- gentamycin, liposome interaction, 362
glassy gelatin, 564
glucose levels, blood, rats, 737
glucose monitoring, iontophoresis, 988
glucuronidation, enantioselective, 125
glucuronides, NMR, FAB-MS, 28
glutamate-induced neuronal damage, 474
glutaraldehyde, cross linking polyvinylalcohol, 578
glutathione dextran conjugate, 1025
glutathione, intrahepatic delivery, 1025
glutathione-S-transferase, 111
glycerides, medium chain, absorption enhancers, 91
glycerol, blood brain barrier, 624
glycoproteins as drug carriers, 105
glycosylated albumin, 466
graph theory, 809
griseofulvin, dissolution, 612
guanylate cyclase, nitric oxide- heme activation, 651
- H1 blockers, anticholinergic activity, 883
hair follicle distribution, 85
haloperidol, blood brain barrier, 624
halothene-induced hepatic necrosis, 266
hamster pouch epithelium, 160
hardness, sucrose, 373
HDL cholesterol, 232
Heidelberg capsule, 719
hepatic acinus, 105
hepatic arterial injection of cisplatin, 342
hepatic blood flow rate, 874
hepatic blood supply, 105
hepatic carcinoma, VX-2, cisplatin delivery, 342
hepatic cell types, 105
hepatic clearance, 105
hepatic clearance, cyclosporine, 254
hepatic elimination, distributed models, 874
hepatic elimination, erythrocyte barrier, 833, 840
hepatic elimination, propranolol, 840
hepatic first pass effect, propranolol, 840
hepatic first-pass metabolism, erythrocyte barrier, 833
hepatic uptake, 140
hepatic uptake, colchicine, 237
hepatobiliary transport, 112, 140
hepatocyte, isolated, colchicine, 237
hepatocytes, 105
hepatotoxicity acetaminophen, 1025
hepatotoxicity, drug induced, 266
heptabarbital pharmacodynamics, 976
histamine-H2-antagonists, cholinergic activity, 709
HOHAHA, NMR, 531
hollow fiber, propranolol delivery, 1052
hollow fibers, polyurethane, 49
HPLC, 2',3'-didehydro-3'-deoxythymidine, 895
HPLC, benoxaprofen glucuronides, 125
HPLC, betamethasone 17 valerate, 431
HPLC, CDRI-81-470, 991
HPLC, centchroman, 10458 oral sustained-release delivery
propranolol, 1052
HPLC, diltiazem in plasma, 428
HPLC, dopamine, 97
HPLC, enantiospecific, metoprolol, 152
HPLC, furegrelate, 53
HPLC, indomethacin, 45
HPLC, insulin derivatives, 171
HPLC, ketorolac, 63
HPLC, oligoglycines, 100
HPLC, prostaglandin E1, 212
HPLC, stereospecific, benoxaprofen glucuronides, 125
human skin, phonophoresis, 697
hyaluronan metabolism, 677
hyaluronan pharmacokinetics in sheep, 677
hyaluronic acid (hyaluronan), 677
hydrocortisone, controlled release SDS from micelles, 241
hydrogel, polyvinyl alcohol, 338
hydrogel, sustained drug release for rectal administration, 338
hydrophilicity, mucosal permeability, 848
hydroxypropyl- β -cyclodextrin, 641
hydroxypropylmethylcellulose, 111In-labeled, 274
hydroxypropylmethylcellulose, 313
hyperlipidemic mice, 232
hypersensitivity reactions, 265
hyperthyroidism, oxazepam pharmacodynamics, 404
hypolipidemic activity, cyclic imides, semicarbazone, 232
- ibuprofen, magnesium oxide interaction, 804
ibuprofen, phonophoresis, 697
idiosyncratic drug reactions, 265
ileocecal junction, 719
imipramine, binding to α 1-acid glycoprotein, 156
imipramine, lung binding, 877
immunomodulator, tilorone, 477
immunopotentiator, muramyl dipeptides, 296
immunosuppressant, cyclosporine, 40
in vitro diffusion, 825
in vitro-in vivo correlation, 313
indigestible solid, GI transit, 719
indomethacin, amphoteric gel, 44
indomethacin, dihydropyridine prodrugs, 667
indomethacin, gastric ulcer, 44
indomethacin, HPLC, 45
indomethacin, ointment, 288
indomethacin, rectal administration, 338
indomethacin, transdermal penetration, 286
indomethacin, transdermal transport, 443
inflammation, neutrophil chemotaxis, 78
infrared spectroscopy, FT-IR/ATR, 608
inhalation, aerosols, 227
injectable emulsion, venous sequelae, 510
inositol phospholipids, synthesis, 218
insulin, immunoreactivity assay, 174
insulin, nasal administration, rats, rabbits, 853
insulin, palmitoyl derivative, 171
insulin, palmitoyl, hypoglycerin effect in rats, 171
insulin, RME, 194
insulin-collagen, co-injection, 813
interface, emulsion, PGE, stability, 212
interfacial peptides, 779
interfacial polycondensation, 714
interferon inducers, effect on N-acetylation, 477
interferon, microspheres, 422
intersubject variability, CGS 16617, bioavailability, 328
intestinal absorption, cyclosporine, 40
intestinal absorption, kinetics, 1056
intestinal brush-border membrane vesicles, 302
intestinal drug absorption, luminal perfusion, 1056
intestinal permeability, L- α -methyl dopa derivatives, 66
intracellular routing and processing, 106
intra gastric pH, 719
intrahepatic delivery, glutathione, 1025
intraindividual variability, bioavailability, 817
intramuscular injection, 167
intramuscular injections, myotoxicity, 766
intramuscular, injection, sex differences, 660
intrasubject variability, CGS 16617, bioavailability, 328
inulin, fluid phase marker, 71
ion exchange, across fiber membrane, 96
ion exchange, drug delivery through membranes, 96
ion pair transport (IPT), 743
ion pairing, effect on pharmacokinetics, 743
ion pairs, cationic drugs-fatty acids, 628
ion transfer, 85
ionization constants, microscopic, 177
ionization equilibrium, 438
ionotropic gelation, 413
iontophoresis, 85, 355
iontophoresis, noninvasive sampling biological fluids, 988
iontophoretic transport, nonionized model compounds, 85
isolated perfused rat liver, 874

- isolated rat liver, 833, 840
isoniazid hepatotoxicity, 266
isopropyl myristate, skin penetration, 628
isoproterenol effects, racial differences, 528
isoproterenol, pharmacodynamics in American negroes and caucasians, 182
- J index, alkanes, 809
jejunum permeability, monkey, rabbit, 857
- keratin extraction, 161
ketorolac tromethamine, oral intramuscular administration, 62
ketorolac, dose proportionality, 62
ketorolac, HPLC, 63
ketorolac, pharmacokinetics in humans, 62
kmeria duperreana, aromatic constituents, 637
kmeriol, isolation, 637
Kupffer cells, 105
- L- α -methyl-dopa, uptake kinetics, intestines, 66
L- α -methyl-dopa-L-phenylalanine, uptake kinetics, intestines, 66
L-dopa ester prodrugs, 501
L-dopa, prodrugs, 501
L-Glutamate, excitatory neurotransmitter, 474
Laplace transform, fast inversion, 931
latexes, film casting, 725
lauric acid, drug ion pairing, 628
LDL cholesterol, 232
lecithin, emulsions, stabilized, 449
lens, timolol diffusion, 772
leucine-enkephalin, nasal absorption, 186
leucine-p-nitroanilide, 966
leukemia cells, P388, multidrug resistant, 690
leukocytes, idiosyncratic drug reaction, 265
levonorgestrel, transdermal delivery, 938
levonorgestrel/estradiol combination, transdermal delivery, 1000
ligandin, 111
lipase, prodrug hydrolysis, 555
lipase, triglycerides emulsions, 449
lipid emulsion, 212
lipiodol, cisplatin suspension, 342
lipopeptide antibiotic, 387
liposomal chloroquine, 787
liposome, aggregation, 362
liposome, cromoglycate, 633
liposome, cyclosporine, 601
liposome, fluid state and gel state, 787
liposomes, aminoglycosides, 362
liposomes, nitroimidazole partitioning, 399
liposomes, transport in neutrophils, 78
lithium pharmacokinetics in rats, 817
liver perfusion, EGF kinetics, 194
liver perfusion, rat, 140
Loo-Riegelman method, 133
lovastatin, decomposition, 20
lovastatin, oxidation, 20
lucifer yellow CH, fluid phase marker, 71, 78
lung drug accumulation, 877
lung mitochondria, basic drug binding, 877
lupus, drug induced, 265
lyophilized powder, moexipril stability, 971
lyophilized sucrose, 961
lysosomal degradation of the glycoprotein carrier, 115
- macromolecular dextran ester prodrugs, 995
macromolecular network, polyvinylalcohol, 578
macromolecular prodrugs, naproxen, 919
macrophage, phagocytosis, interferon microspheres, 422
macrophages, phagocytosis, 296
madin darby canine kidney (MDCK), epithelial cell monolayer, 71, 78
magnoliaceae, aromatic constituent, 637
malignant cell lines, HL60, BG-1, BG-3, 218
mammary adenocarcinoma in CD8FI mice, 863
mean absorption time, 4
mean residence time, 4, 260
medroxyprogesterone, dissolution, 612
melting points, narcotic analgesics, 825
membrane peptides, 779
membrane proteins, interfacial amino acids, 779
membrane transport of ion pairs, 743
membrane transport, phenytoin, 332
metabolism, buccal epithelium, 160
metabolism, in skin, 119
metabolites sulfasalazine, 1067
methotrexate, carboplatin interaction, 492
metoclopramide, lung binding, 877
metoprolol, enantiospecific HPLC, 152
metoprolol, radioreceptor assay, 152
metronidazole, complex with sodium urate, 58
metronidazole, photodegradation, 58
mice, athymic, 33
micelle, SDS, 241
micelles, phenytoin prodrugs, 555
Michaelis-Menten elimination, 4, 260
Michaelis-Menten kinetics, hyaluronan, 677
microbial models of mammalian metabolism, 982
microcalorimetry, lovastatin, 20
microcapsules, cellulose acetate butyrate coated, 517
microcapsules, theophylline, 714
microencapsulation, 413
microfluidizer, 748
microindentation sucrose crystals, 1060
microindentation, fracture toughness, 373
micropellets, dapsone, 945
microporous membranes, controlled drug release, 241
microspheres theophylline, 418
microspheres, 413
microspheres, core size, 418
microtubule, colchicine, 237
microwave technique, skin sectioning, 740
moexipril lyophilization, 971
moexipril stability, 971
moexipril, ACE inhibitor, 759
molecular branching, 809
molecular connectivity, 497
molecular fragments, data base search, 497
molecular modeling, phenobarbital N-glucosides, 458
moment analysis, 4, 133
moment analysis, biliary transport, 140
mono-N-desmethyldiazepam, 379
monoamine oxidase (MAO) binding of basic drugs, 877
monocytes, idiosyncratic drug reaction, 265
monolayer, madin darby canine kidney (MDCK), 71
morphinan, conjugation, 28
morphine, solubility and dissociation constants, 147
motion sickness, scopolamine, 481
mucosal absorption, 848
multidrug resistance, P388 cells, 690
multilaminar adhesive device, propranolol delivery, 753
multiple dosing, 731
multiple indicator dilution method, 194
multiple internal reflectance infrared (MIR), ibuprofen-MGO interaction, 804
multiple-dose pharmacokinetics, adiazepam, 379
muramyl dipeptide, immuno potentiator, 296
muramyl dipeptide adjuvant, 748
muramyl dipeptide, 748
muscle damage, i.m. injection, in vitro model, 167
mutagenesis, protein stability, 903
myeloperoxidase, idiosyncratic drug reaction, 265
myotoxicity, 766
myotoxicity, binary solvent mixtures, 766
myotoxicity, intramuscular injections, 766
myotoxicity, in rat, 167
- N-(1-(2-thienyl)cyclohexyl)piperidine, dissociative anesthetic, 474
n-alkanoic acids, iontophoresis, 85

- n-alkanols, iontophoresis, 85
 N-alkyl-1,2-diphenylethanolamines, antiarrhythmic activity, 254
 N-demethylation, dextromethorphan, 13
 N-glucosides, phenobarbital, 458
 N-methyl-D-aspartate (NMDA) receptor, 474
 N-nitrosodiisopropanolamine, GC/MS, 892
 N-phosphinylamino-1,2,5,6-tetrahydropyridines, analgesia, 737
 N-phosphinylamino-1,2,5,6-tetrahydropyridines, blood glucose levels, 737
 nalmeferene, 3-O-glucuronide, 28
 naloxone skin penetration, 246
 nanoparticles, 413
 naphazoline, skin penetration, 628
 naproxen bioavailability in pigs, 919
 naproxen dextran ester prodrugs, 995
 naproxen dihydropyridine prodrugs, 667
 naproxen regeneration, 995
 naproxen, macromolecular prodrug, 919
 narcotic analgesic, dissociation constants, 147
 narcotic analgesics, permeability coefficients, 825
 narcotic analgesics, pH solubility profiles, 147
 narcotic analgesics, solubility, 147
 narcotic antagonist, nalmeferene, 28
 nasal absorption, progesterone, 848
 near-infrared spectroscopy, sucrose water content, 961
 nephrotoxicity, aminoglycosides, 362
 neuroleptics, rat brain receptor, 571
 neuroleptics, receptor binding versus effect, 571
 neuropeptides, rectal absorption, 91
 neutrophil extravasation, 78
 neutrophils, idiosyncratic drug reaction, 265
 nitrate esters activation, 651
 nitric oxide, endothelium derived, 651
 nitroglycerin activation, 651
 nitroimidazoles, partitioning in n-octanol/saline, 399
 nitroimidazoles, QSAR pharmacokinetics, 399
 nitrosamines, GC/MS, 892
 NMDA receptor binding, 474
 NMR, HMBC, COSY, INEPS, HETCOR spectra, 30
 NOESY, NMR, 531
 nomifensine, toxicity, 265
 noncompartmental parameters, 731
 noninvasive imaging, atherosclerosis, 1011
 noninvasive sampling, iontophoresis, 988
 nonlinear pharmacokinetics, atenolol, 250
 nonlinear regression, 133
 nonsteroidal antiinflammatory (NSAID) prodrugs, 867
 nonsteroidal antiinflammatory drugs, 667
 nonsteroidal antiinflammatory drugs, benoxaprofen, 125
 nuclear magnetic resonance (NMR) cis/trans chlorprothixene, 706
 nuclear magnetic resonance (NMR) spectroscopy, two dimensional, 531
 nuclear Overhauser effect (NOE) chlorprothixene isomers, 706
 nutrient drug interaction, 332
 nylon microcapsules, 714
- O-demethylation, dextromethorphan, 13
 obese children, volume of distribution of antibiotics, 486
 ocular aqueous humor, drug concentration, 887
 ocular drug delivery, timolol in rabbits, 772
 ocular kinetics of timolol, model, 772
 ocular transport, 5-iodo-2'-deoxyuridine prodrugs, 887
 oleic acid, drug ion pairing, 628
 oligo glycines, models for peptide absorption, 100
 oligoglycines, HPLC, reverse phase, 100
 opioids, endogenous, 1
 oral cephem, transport, 308
 oral delivery system, phenylpropanolamine, 49, 844
 oral drug delivery, microspheres, 413
 organic nitrate esters, 651
 otitis media, experimental animal models, 279
 ovariectomized rats, estradiol administration, 592
 oxazepam, natural products, 2
- oxazepam, pharmacokinetics in hyperthyroidism, 404
 oxidation, protein degradation, 903
 oxprenolol release, 313
 oxygen radicals in biology and medicine, 900
- p-aminohippurate, transport, 954
 p-hydroxyketorolac, metabolite of ketorolac, 62
 palmitoyl derivative, insulin, 171
 pancreatic lipase, 449
 pancreatic lipase, prodrug hydrolysis, 555
 Parkinson's disease, L-dopa prodrugs, 501
 particle size analysis, 748
 particle size, microspheres, 418
 particle size, suspensions, 227
 partition coefficient, etoposide, 408, 411
 partition coefficients, narcotic analgesics, 825
 partitioning of nitroimidazoles, 399
 passive transport, jejunum, 857
 penetration enhancer, azone, 798
 penetration enhancers, by ion pairing, 628
 penetration enhancers, transdermal, amino acetate, 286
 peptidase inhibitor, EDTA, 91
 peptide degradation pathway, 387
 peptide, lipophilic derivatives, 171
 peptides hormones, endocytosis, 194
 percutaneous absorption, 931
 percutaneous absorption, indomethacin, 286
 percutaneous absorption, phonophoresis, 697
 permeability coefficient, skin, 443
 permeability, jejunum, 857
 permeation enhancers, ethyl acetate, ethanol, 938
 petrolatum ointments, indomethacin, 288
 pH-profiles, daptomycin, 387
 pH-solubility profiles, narcotic analgesics, 147
 phagocytosis by neutrophils, 78
 phagocytosis, macrophage, interferon microspheres, 422
 phagocytosis, macrophages, 296
 pharmacodynamic model, drug targeting, 367
 pharmacodynamics, adinazolam, 379
 pharmacodynamics, barbiturates, 976
 pharmacodynamics, oxazepam, 404
 pharmacokinetic parameters, nitroimidazoles, 399
 pharmacokinetics in elderly, 379
 pharmacokinetics, aspirin, 660
 pharmacokinetics, carboplatin in cancer patients, 492
 pharmacokinetics, cromoglycate, man, 633
 pharmacokinetics, cyclosporine, 254, 601
 pharmacokinetics, drug targeting, 367
 pharmacokinetics, fenoldopam, 702
 pharmacokinetics, hyaluronan, sheep, 677
 pharmacokinetics, phenylpropanolamine, 844
 pharmacokinetics, scopolamine, 481
 pharmacokinetics, sulfasalazine, 1067
 pharmacophores, 497
 phenethylamines, activity, 254
 phenindamine, antiperspirant, 883
 phenobarbital N-glucosides, stability, 458
 phenobarbital pharmacodynamics, 976
 phenol red, liver uptake, 140
 phenylbutazone-induced agranulocytosis, 270
 phenylethylamine, lung binding, 877
 phenylpropanolamine, bioavailability, 274
 phenylpropanolamine, sustained release, 49
 phenylpropanolamine, sustained release, pharmacokinetics, 844
 phenytoin, 3-hydroxy, long chain fatty acid esters, 555
 phenytoin, intestinal absorption, 332
 phenytoin, lupus, 268
 phenytoin, prodrug hydrolysis, 555
 phonophoresis, transdermal, 355
 phonophoretic drug delivery, 355
 phosphatidylinositol-4,5-diphosphate-containing liposomes, 362
 phosphatidylcholine, cisplatin-lipiodol suspension, 342
 phosphatidylinositol, ether linked derivatives, 218
 phospholipid analogs, alkyl ether, 218

- phosphoribosyl pyrophosphate, after uridine diphosphoglucose doses, 863
- photodegradation, metronidazole, 58
- piperazines, microscopic ionization constants, 177
- plasmodium berghei infections, 787
- platelet aggregation, nitric oxide effects, 651
- platelet-activated factor, lipid analogs, 218
- platinum, total, ultrafilterable in plasma, 492
- poly(vinyl alcohol)micromatrices, cross-linked, 578
- polycarbonate disks, collagen-coated, 163
- polycarbonate membrane, 78
- polycarbonate membranes, endothelial brain microvessel cell, 624
- polyethylene glycol 400, myotoxicity, 766
- polylactide microspheres containing muramyl dipeptide, 296
- polymeric films, controlled drug release, 725
- polymorphism, dextromethorphan metabolism, 13
- polymorphonuclear neutrophil, 78
- polysaccharide, chitosan, 413
- polyurethane, segmented, fibers, 49
- polyvinyl alcohol hydrogel, 338
- polyvinyl alcohol-methyl acrylate copolymers, crystalline, 844
- portacaval shunt, cyclosporine, 254
- potentiometric titration, piperazines, 177
- powder x-ray diffractometry, carbamazepine, 1017
- practolol, toxicity, 265
- precipitation, protein stability, 903
- preformulation etoposide, 408
- procainamide, acetylation, 477
- procainamide, lung binding, 877
- procainamide-induced lupus, 267
- procainamide-tilorone, interaction, 477
- prodrug hydrolysis, phenytoin, 555
- prodrugs, ACE inhibitors, 1043
- prodrugs, NSAID, 867
- progesterone, blood brain barrier, 624
- progesterone, controlled release SDS from micelles, 241
- progesterone, hydroxylated, 848
- propranolol HCl, in polymeric film, 725
- propranolol, blood brain barrier, 624
- propranolol, hepatic elimination, 840
- propranolol, hollow fiber delivery system, 1052
- propranolol, skin permeation, 753
- propylene glycol, myotoxicity, 766
- prostaglandin E1, dehydration, 212
- prostaglandin E1, emulsion, stability in emulsion, 212
- prostaglandin E1, HPLC, 212
- protein binding of drugs, 105
- protein binding of drugs, hydrophobic and electrostatic, 156
- protein binding, effect on hepatic elimination, 874
- protein kinase C inhibitors, 218
- protein kinase C, HL60 cells, 218
- protein pharmaceuticals, stability, 903
- protein, chemical stability, 903
- protein-lipid interactions, 779
- proteinase inhibitors, 38
- proteolysis, 903
- proton-coupled uphill transport, 302
- protonophore, FCCP, 302
- proxiphylline, cross-linked poly(vinyl alcohol), 578
- psychomotor performance, adinazolam, 379
- pulmonary drug delivery, 633
- pump incompatibility, cyclosporine, 601
- pyridinium salts, prodrugs, 667
- pyrilamine, antiperspirant, 883
- quantitative structure-activity relationships (QSAR), nitroimidazoles, 399
- quinine, lung binding, 877
- racemization, protein degradation, 903
- racial differences, isoproterenol effect, 528
- radioreceptor assay, metoprolol, 152
- radiosynthesis (\pm)I-iodo-MK-801, 474
- radiotelemetry, GI transit, 719
- raffinose monolaurate, 959
- random effects, statistical model, 328
- rat foot pad, sweat glands, 883
- rauwolfia serpentina, reserpine assay, 521
- reactive metabolites in leukocytes, 265
- receptor binding, neuroleptics, 571
- receptor internalization, EGF, 194
- receptor mediated endocytosis, peptides, 194
- receptor occupancy, flunitrazepam, 585
- receptor-mediated endocytosis, 105
- receptosome, 106
- rectal absorption, 5'-deoxy-5-fluorouridine, 323
- rectal absorption, L-dopa esters, 501
- rectal absorption, L-dopa prodrugs, 501
- rectal absorption, peptides, in rats, 91
- rectal absorption, progesterone, 848
- rectal administration of indomethacin, 338
- renal failure, transport function, 954
- reserpine, circular dichroism, 521
- reversible metabolism, fenoldopam, 702
- ribavirin, blood brain barrier, 624
- riboflavin effect on, 1067
- ROESY, NMR, 531
- rotating diffusion cell, ion pairs, 628
- salicylate esters, skin absorption, 119
- salicylic acid, diester derivative, 33
- salicylic acid, HPLC, 46
- salicylic acid, in polymeric film, 725
- salicylic esters, skin metabolism, 33
- scintigraphy, gastrointestinal transit, 274
- scopolamine pharmacokinetics in normal subjects, 481
- scopolamine, bioavailability, 481
- SDS micelles, 241
- sebacyl chloride, 714
- semicarbazone, 232
- senile dementia, tacrine, 924
- serine proteinase inhibition, 38
- sex differences, asparin pharmacokinetics, 660
- sex differences, intramuscular injection, 660
- sialic acid, 106
- site specific absorption, moexipril, 759
- skin barrier function, effect of age, 949
- skin drug metabolism, 119
- skin graft, human, in athymic mice, 33
- skin irritation, fatty acids, 246
- skin layer separation, 740
- skin model, two-layer, 931
- skin penetration enhancers, fatty acids, 246
- skin penetration model, 931
- skin permeability, 355
- skin permeability, azone, 798
- skin permeability, narcotic analgesics, 825
- skin permeation of cationic drugs, 628
- skin permeation, propranolol, 753
- skin pores, 355
- skin retention, 740
- skin sectioning, microwave, 740
- skin transport, pH effect, 443
- skin, drug transport, 119
- skin, excised human, 628
- skin, human cadaver, 825
- skin, human facial drug transport, 119
- skin, human, 33
- skin, iontophoresis, 988
- skin, metabolism, 33
- skin, nude rats, iontophoresis, 85
- skin, phonophoresis, 355
- skin, transport of basic and acidic drugs, 443
- sleeping time, barbiturates, 976
- small bowel transit time, 719
- snake skin, percutaneous absorption, 286
- snakeskin transport, 443
- sodium cromoglycate, pharmacokinetics, 633

- sodium dodecylsulfate (SDS) micelles, 241
sodium salicylate, skin penetration, 628
sodium taurodihydrofusidate, absorption enhancer, 853
sodium urate, complex formation, 58
solid surfactant solution, ciclosporin, 958
solid-state interaction, ibuprofen-MGO, 804
solid/liquid boundary, 438
solubility indomethacin, 445
solubility, narcotic analgesics, 147, 825
solubilization, of drugs in micelles, 241
species correlation, jejunum permeability, 857
sprays, aerosol, 227
stability, contraceptive drugs, 1000
stability, calorimetry, 20
stability, moexipril, 971
stability, etoposide, 408
stability, oxprenolol preparations, 313
stability, PGE, 212
stability, protein pharmaceuticals, 903
stability, phenobarbital N-glucosides, 458
stability-indicating, HPLC, betamethasone 17-valerate, 431
statistical moment, 931
stereoselective metabolism of warfarin, 982
stereoselective transport, 302
stratum corneum occlusion, 949
stratum corneum, 85, 753, 798, 931
structure elucidation, by two dimensional NMR
structure-pharmacokinetic relationships, valpromide derivatives, 683
subcutaneous injection, insulin-collagen, 813
subcutaneous tissue, peptidases, 813
succinylsulfathiazole, sustained release microcapsules, 517
sucrose crystals, deformation, 1060
sucrose crystals, fracture toughness, 373
sucrose water content, 961
sucrose, fluid phase marker, 71
sucrose-monolaurate, 959
sufentanyl, solubility and dissociation constants, 147
sugar esters, solubilizers, 958
sulfamethoxazole, FT-IR/ATR analysis, 608
sulfamethoxazole, otitis media, pharmacokinetics, 279
sulfasalazine metabolites, 1067
sulfonamides, binding to carbonic anhydrase, 205
sulfonamides, toxic reactions, 270
sulfoxide metabolites, H₂-antagonists, 709
surface area, colestipol-HCl, 619
surfactants, biodegradable, 958
surfactants, effect dissolution, 612
suspension, pressurized, nonaqueous for aerosols, 227
sustained release, phenylpropanolamine, 49, 844
sustained release, propranolol, 1052
swellable micromatrices, 578
swelling oxprenolol release, 313
- tablets, controlled release of oxprenolol, 313
tacrine, tissue distribution, 924
targeted drug delivery, by neutrophils loaded with liposomes, 78
taurocholate, hepatic elimination, 874
taurodeoxycholate (TDC) micellar solutions, 449
teicoplanin dextrose adducts, 1032
teicoplanin, gleicopeptide antibiotic, 1032
temperature, phonophoresis, 697
tertiary basic drug, lipid solubility, 877
testosterone, administration by bolus, 641
testosterone, administration by episode-like pulses in rats, 641
testosterone, behavioral and physiological effects, 641
testosterone, blood brain barrier, 624
testosterone, buccal administration, 641
testosterone, controlled release SDS from micelles, 241
tetraethylammonium transport, 954
theophylline, bioavailability in dogs, 1039
theophylline, cross linked poly(vinyl alcohol), 578
theophylline, microcapsules, 714
theophylline, microspheres, 418
thermal analysis, ibuprofen-MGO interaction, 804
thermodynamics, lovastatin decomposition, 20
thermodynamics, phenobarbital N-glucosides, 458
thioester prodrugs, NSAID, 867
thrombosis, nitric oxide effects, 651
thromboxane synthetase inhibitor, furegrelate, 53
ticrynafen hepatotoxicity, 266
ticrynafen, toxicity, 265
tilorone, immunomodulator, 477
tilorone-procainamide interaction, 477
timolol, diffusion in lens, 772
tobramycin, distribution in obese children, 486
TOCSY, NMR, 531
topological index, 809
toxicity, cyclosporine, 601
toxicophores, 497
trace analysis, nitrosamines, 892
transcellular transport, albumin, 466
transcellular vesicular transport, 71
transdermal contraceptive devices, 1000
transdermal delivery, 355
transdermal delivery, contraceptive drugs, 1000
transdermal delivery, narcotic analgesics, 825
transdermal delivery, propranolol, 753
transdermal drug transport, 119
transdermal patches, clonidine, scopolamine, in vitro release profile, 346
transdermal penetration enhancers, 286, 443
transdermal penetration enhancers, ion pairing, 628
transdermal transport, 33
transdermal transport, azone, 798
transepidermal water loss, 949
transepithelial electrical resistance, 71
transferrin, RME, 194
transition-state analogue inhibitors, 186
transmembrane domains of membrane proteins, 779
transpeptidation, 903
transpeptidation, daptomycin, 387
transport, β -lactam, oligopeptide, 308
transport inhibitors, ouabain, sulhydryl reagents, 237
transport of ion pairs across membranes, 743
transport receptor, 194
transport, across blood brain barrier, 466
transport, buccal epithelium, 160
transport, cellular, 71
transport, ceftibuten, 302
transport, dipeptide, 308
transport, facilitated, iontophoresis, 85
transport, neutrophil-mediated, 78
transport, non-Fickian, 564
transport, p-aminohippurate, 954
transport, passive in jejunum, 857
transport, transcellular vesicular, 71
triglyceride content, VLDL, 232
triglyceride emulsions, hydrolysis, 449
trimethoprim, FT-IR/ATR analysis, 608
trimethoprim, otitis media, pharmacokinetics, 279
tripelennamine, antiperspirant, 883
tumor bearing mice, uridine diphosphoglucose administration, 863
two-dimensional (2D) NMR, 531
- ultrasonic drug delivery, 355
ultrasound, phonophoresis, 697
uranyl nitrate, renal toxicity, 954
urate, sodium, complex formation with metronidazole, 58
urea, blood brain barrier, 624
uridine diphosphoglucose, administration tumor bearing mice, 863
uridine triphosphate, after uridine diphosphoglucose doses, 863
urinary excretion, platinum, 492
ursolic acid, NMR, 531
- vaccine adjuvant, muramylpeptides, 748
vaginal absorption, progesterone, 848
valence connectivity index, 497

valnoctamide, pharmacokinetics, 683
valproic acid, pharmacokinetics, 683
valpromide derivatives, structure-pharmacokinetics relationships,
683
vasodilation, nitric oxide, 651
verapamil, antiarrhythmic activity, 254
verapamil, internal standard for diltiazem HPLC, 428
vesicles, reverse-phase evaporation lipid, 78
vincristine efflux from P388 cells, 690
volume of distribution, antibiotics in obese children, 486
Wagner-Nelson method, 133

warfarin microbial metabolism, 982
water determination, near IR, 961
water swelling, gelatin matrices, 564
x-ray diffraction, carbamazepine, 1017
xylocaine, myotoxicity upon i.m. injection, 167
zero-flux conditions at a dissolution surface, 436
zero-order release, oxprenolol, 313
zero-order release, succinylsulfathiols, 517
zidovudine, pharmacokinetics, rats, 734
zomepirac, toxicity, 265